After targeted agents, a novel bispecific in EGFR-mutant lung cancer improves PFS.

Published Date: 03 Jun 2024

FDA approval could be hampered by a trial conducted in China, though.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

In myelofibrosis, combinations of rufolitinib reduce spleen volume.

2.

Treatment of Oligometastatic EGFR-Mutant Lung Cancer

3.

Aster Whitefield Hospital, with 506 beds, opened.

4.

New First-Line Option for Advanced ALK-Positive Lung Cancer

5.

AI Model Has Promise for Predicting Checkpoint Inhibitor Activity in NSCLC


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot